Results 51 to 60 of about 29,486 (214)

Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a mRNA-1273 vaccine recipient. [PDF]

, 2022
We report a case of recurrent tender, multifocal lymphadenopathies associated with B-symptoms, clinically mimicking lymphoma in a mRNA-1273 vaccine recipient after a recent Epstein-Barr virus (EBV) infection.
Girardin, F.R., Greub, G., Livio, F., Pantaleo, G., Tzankov, A.   +4 more
core   +1 more source

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

Vaccines, 2023
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines.
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Donchida Srimuan, Thaksaporn Thatsanathorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan   +16 more
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Human Vaccines & Immunotherapeutics, 2023
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still ...
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R. Lowy, Ligia A. Pinto   +8 more
doaj   +1 more source

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

International Journal of Infectious Diseases, 2023
Intro: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration.
A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari   +5 more
doaj   +1 more source

Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database [PDF]

, 2023
Introduction: Since the first COVID-19 messenger RNA vaccines became available globally for emergency or conditional use, post-marketing surveillance activities have been implemented for the monitoring of any adverse events that might arise in daily ...
Bonaldo G., Broccoli M., Montanaro N., Motola D., Santi Laurini G.   +4 more
core   +1 more source

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

Human Vaccines & Immunotherapeutics, 2023
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e ...
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris   +6 more
doaj   +1 more source

Sudden Sensorineural Hearing Loss Following Immunization With BNT162b2 or mRNA-1273:A Danish Population-Based Cohort Study [PDF]

, 2023
Objective: To compare the occurrence of sudden sensorineural hearing loss following immunization with BNT162b2 (Comirnaty®; Pfizer BioNTech) or mRNA-1273 (Spikevax®; Moderna) to the occurrence among unvaccinated individuals.
Cleary, Brian, Damkier, Per, Hallas, Jesper, Jensen, Peter B., Ladebo, Louise, Lund, Lars Christian, Schmidt, Jesper H.   +6 more
core   +1 more source

Relationship between immune response to SARS-CoV2 vaccines and development of breakthrough infection in solid organ transplant recipients: the CONTRAST cohort [PDF]

, 2023
Background: SARS-CoV-2 vaccination in solid organ transplant (SOT) is associated with poorer antibody response (AbR) compared to non-SOT recipients. However, its impact on the risk of breakthrough infection (BI) should yet be assessed.
Bonazzetti, Cecilia, Borgese, Laura, Busutti, Marco, Caroccia, Natascia, Comai, Giorgia, Fanì, Francesca, Fornaro, Giacomo, Gamberini, Chiara, Giannella, Maddalena, Gibertoni, Dino, Lazzarotto, Tiziana, Miani, Beatrice, Morelli, Maria Cristina, Pascale, Renato, Pasquini, Zeno, Potena, Luciano, Rinaldi, Matteo, Salvaterra, Elena, Scudeller, Luigia, Tamé, Mariarosa, Tazza, Beatrice, Viale, Pierluigi   +21 more
core   +1 more source

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

International Journal of Infectious Diseases
Objectives: To assess the safety and immunogenicity of a fourth vaccination (second booster) in individuals aged ≥75 years. Methods: Participants were randomized to BNT162b2 (Comirnaty, 30 µg) or messenger RNA (mRNA)-1273 (Spikevax, 100 µg).
Jannik Stemler, Lusine Yeghiazaryan, Christoph Stephan, Kristin Greve-Isdahl Mohn, Antonio-José Carcas-Sansuan, Esperanza Romero Rodriguez, José Moltó, Itziar Vergara Mitxeltorena, Tobias Welte, Birutė Zablockienė, Murat Akova, Ullrich Bethe, Sarah Heringer, Jon Salmanton-García, Julia Jeck, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Lena M. Biehl, Jan Grothe, Sibylle C. Mellinghoff, Julia A. Nacov, Julia M. Neuhann, Rosanne Sprute, Jesús Frías-Iniesta, Riya Negi, Colette Gaillard, Gurvin Saini, Alejandro García León, Patrick W.G. Mallon, Christine Lammens, An Hotterbeekx, Katherine Loens, Surbhi Malhotra-Kumar, Herman Goossens, Samir Kumar-Singh, Franz König, Martin Posch, Philipp Koehler, Oliver A. Cornely   +39 more
doaj   +1 more source